Humacyte, Inc. (HUMA)

4.4100 +0.0100 (+0.23%) At close: 04:00PM EDT

Humacyte, Inc.

2525 East North Carolina Highway 54
Durham, NC 27713
United States
919 313 9633
https://www.humacyte.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 183

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Laura E. Niklason M.D., Ph.D.	Founder, President, CEO & Director	899.25k	N/A	1963
Mr. Dale A. Sander	CFO, Chief Corporate Development Officer & Treasurer	704.33k	N/A	1960
Dr. Juliana L. Blum Ph.D.	Co-Founder & Executive Advisor	N/A	N/A	N/A
Mr. Harold Alterson	Senior Vice President of Quality	N/A	N/A	N/A
Dr. Yang Cao M.D., Ph.D.	Chief Regulatory Officer	N/A	N/A	1966

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Corporate governance

Humacyte, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.